TY - JOUR
TI - Long-term safety of deferiprone treatment in children from the mediterranean region with beta-thalassemia major: The DEEP-3 multi-center observational safety study
AU - Botzenhardt, S.
AU - Felisi, M.
AU - Bonifazi, D.
AU - Del Vecchio, G.C.
AU - Putti, M.C.
AU - Kattamis, A.
AU - Ceci, A.
AU - Wong, I.C.K.
AU - Neubert, A.
AU - DEEP consortium (collaborative group)
JO - Haematologica-the hematology journal
PY - 2018
VL - 103
TODO - 1
SP - e1-e4
PB - Ferrata Storti Foundation
SN - null
TODO - 10.3324/haematol.2017.176065
TODO - alanine aminotransferase;  deferiprone;  deferiprone;  iron chelating agent, abdominal pain;  agranulocytosis;  alanine aminotransferase level;  Albania;  aminotransferase blood level;  arthralgia;  arthropathy;  beta thalassemia;  blood transfusion;  body weight gain;  chelation therapy;  child;  cohort analysis;  Cyprus;  diarrhea;  drug safety;  drug withdrawal;  dyspepsia;  Egypt;  endocrine disease;  fatigue;  female;  follow up;  Greece;  hearing impairment;  heart disease;  hospitalization;  human;  hypersalivation;  incidence;  iron chelation;  Italy;  joint swelling;  kidney dysfunction;  knee;  Letter;  leukopenia;  long term care;  major clinical study;  male;  monotherapy;  multicenter study;  nausea and vomiting;  neurologic disease;  neutropenia;  observational study;  preschool child;  school child;  skin manifestation;  Southern Europe;  splenectomy;  splenomegaly;  thrombocytopenia;  Tunisia;  age;  beta thalassemia;  clinical trial;  complication;  iron overload;  Southern Europe;  treatment outcome, Age Factors;  beta-Thalassemia;  Child;  Deferiprone;  Humans;  Iron Chelating Agents;  Iron Overload;  Mediterranean Region;  Treatment Outcome
TODO - null
ER -